Video: Dr. Casella reviews vitamin B3 for glaucoma management

October 20, 2020
Brooke Beery, Associate Editor
Brooke Beery, Associate Editor

Brooke Beery is Assistant Editor of Optometry Times®.

,
Benjamin P. Casella, OD, FAAO

A world-first clinical trial led by the Centre for Eye Research Australia shows vitamin B3 (nicotinamide) could play an important role in protecting against nerve cell damage that leads to blindness in glaucoma patients. Chief Optometric Editor, Ben Casella, OD, FAAO, says it's exciting news, but more research needs to be done.

Related: Glaucoma & ocular surface preservation: Key factors for ODs to consider